Shots:

• The US FDA approval is based on P-III SAMURAI and SPARTAN- evaluated the safety and efficacy of Reyvow vs PBO for the acute treatment of migraine in adults- resulted in meeting its 1EPs of pain freedom and freedom from most bothersome symptom
• The Reyvow will be available in retail pharmacies following its recommended controlled substance classification- currently under review by DEA and is expected within 90 days of its FDA approval
• Reyvow (lasmiditan) targets 5-HT1F receptors- first and only approved therapy in a new class of acute treatment for migraine- with/out aura in adults and will be available in oral doses of 50 mg- 100mg & 200mg               

Click here to­ read full press release/ article | Ref: Eli Lilly | Image: Pharmaceutical Technology